![]() ![]() has the right to rescind, revoke, or amend this program at any time without notice. Offer void where prohibited by law, taxed, or restricted. Patients are not eligible if they are under 18 years of age or are covered in whole or in part by any state program or federal healthcare program, including, but not limited to, Medicare or Medicaid (including Medicaid managed care), Medigap, VA, DOD, or TRICARE. This offer is only valid in the United States and Puerto Rico and is not transferable. By participating in this program, you are certifying that you will comply with the terms and conditions described in the Restrictions section below. Participation in this program must comply with all applicable laws and regulations as a pharmacy provider. ![]() When you apply for this offer, you are certifying that you have not submitted a claim for reimbursement under any federal, state, or other governmental programs for this prescription. For any questions regarding Therapy First Plus online processing, please call the Help Desk at 1-80. Reimbursement will be received from Therapy First Plus. A valid Prescriber ID# is required on the prescription. Eligible patients are responsible for as little as $10, with up to $8,000 in annual savings. Submit the claim to the primary Third Party Payer first, then submit the balance due to Therapy First Plus as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code (eg, 8). As a condition of payment, you certify that you are in compliance with all program rules, terms, and conditions, as well as with any obligations to provide notice of your participation in this program to third-party payers as required by law, contract, or otherwise. When you use this card, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental programs for this prescription. Patients with questions about the offer should call 1-88. By using this offer, you are certifying that you meet the eligibility criteria (not a member of a federal, state, or government insurance program) and will comply with the terms and conditions described in the Restrictions section below. ![]() The overall safety and tolerability profile was generally consistent with that observed in oral aripiprazole trials.ĪLAI is a viable treatment option for patients with schizophrenia as it has demonstrated an acceptable efficacy as well as safety and tolerability profile.In order to redeem this offer you must have a valid prescription for ABILIFY MAINTENA ® (aripiprazole). The efficacy, safety and tolerability of ALAI in maintenance treatment of schizophrenia has been well documented in a number of clinical trials.ĪLAI has demonstrated efficacy in the acute treatment of schizophrenia. The nature of schizophrenia requires continuous medication to prevent relapse.īoth clinical trials and observational research has shown that adherence to antipsychotic treatment is low, despite the availability of effective antipsychotic treatment.Īs continuous medication delivery is essential for the long-term treatment of schizophrenia, long-acting injectables have the potential to have a positive impact on adherence, but still their use in schizophrenia remains low.Īripiprazole long-acting injectable (ALAI) demonstrated prevention of relapse in schizophrenia. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |